Prof Nikhil Vasdev

Promoted to ‘Professor of Robotic Surgery and Urology’ at @uniofhertslms @UniofHerts. Grateful to my referees,family and friends @prokarurol @DrManiMenon @JoCresswell4 @Jburodoc @MrTimLane @Dr_Andrology @AdamSewellJones @MikeChilvers1 @KarelDecaestec1 @UrologyTiong @JulieAnneCEO

Many thanks @AnkurMuk @hayesjdb Wes Hutchins and @BAUSurology 🇬🇧 for the very kind invitation. I thoroughly enjoyed the podcast and the engaging discussion.

Another outstanding @VattikutiRobotx meeting in Miami 🇺🇸 , bringing together global leaders in multi-specialty robotic surgery. Inspiring discussions, expanding multi-centre collaborations, and exciting progress in AI implementation strategies—all focused on advancing surgical and robotic care across both the developing and developed world. Great to interact with all the medical students who attended from multiple international universities. Grateful for the invitation and the warm hospitality. Looking forward to continuing these important collaborations. @MBhandariUrol @MMenonMD @AkshayB_MD @stingrai78 @prokarurol @CraigRogersMD

The future of surgery is collaborative — powered by intelligence. Wouter Bogaert, Computer Vision Engineer at Orsi Academy, presents the Surgical Copilot — a vision-language AI model designed to understand prostatectomies, marking a major leap toward real-time surgical assistance. From advanced data collection to generating intelligent Q&A pairs, this innovation is shaping the next phase of AI-driven surgery. A remarkable contribution from the ORSI Group, pushing the boundaries of AI in surgical practice. #VattikutiFoundation #KSAwards #ArtificialIntelligence #SurgicalInnovation #MedTech @prokarurol @danieleamparore @Fede_Piramide @MBhandariUrol @alexmottrie @kinjutweets @UroZedman @nikhilvasdevuro @alexmottrie @pidebacker @orsiacademy @FedericoLavagno

@VattikutiRobotx Great to be at the innovative Vattikuti Foundation meeting in Miami 🇺🇸 focusing on improving robotic prostate cancer care globally.#AI

The Royal College of Surgeons of England Lister Robotic Urology Fellowship (12 Months) We are delighted to announce that applications are now open for our high-volume Robotic Urology Fellowship. This 12-month fellowship offers: •Extensive hands-on experience in robotic urological surgery •Exposure to a high-volume surgical programme •Opportunities to engage in cutting-edge academic research and innovation Interview Dates: May 2026 Fellowship Start Dates: •Intake 1: October 2026 •Intake 2: March 2027 This is an exceptional opportunity for trainees seeking to develop advanced expertise in robotic urology within a leading academic and clinical environment. @enherts @RCSEng @BAUSurology @MrTimLane @Dr_ABrodie enherts-tr.nhs.uk/careers/vacanc…

Looking forward to speaking at the @ProstateUK Specialist Cancer Conference on "Tomorrow’s tools Today: How AI is transforming prostate cancer care" coming Wednesday 25th March. prostatecanceruk.org/for-health-pro…

#EAU26 #Latebreaking

Our Research from The @UniofHerts and @enherts is being presented as Late-Breaking Presentation at #EAU26 @Uroweb linkedin.com/posts/prof-nik…

Our Partial Mapped Resection technique with the Lister Neurosafe being presented by @MatthewFeyissa at #EAU26. This technique improves functional outcomes in patients undergoing Robotic Prostatectomy @enherts @UniofHerts

@UroDocAsh @niyatilobo @AlisonBirtle @ParamMariappan @RobertoContieri Thank you so much, Ashish. It was truly an honor for both Niyati and me to host dinner for you and to have so many friends together for such a wonderful evening.

Niyati and Nik – thank you for hosting such a wonderful dinner and for the warm hospitality. A truly perfect start to #EAU26. Grateful to everyone who came out to celebrate and spend time together @niyatilobo @nikhilvasdevuro @AlisonBirtle @ParamMariappan @RobertoContieri @drtanws @jteoh_hk

Published today - "AI decision support for increasing prostate biopsy efficiency: a retrospective multicentre, multiscanner study" pubmed.ncbi.nlm.nih.gov/41718862/

Thank you, @MrTimLane and @ShafiAhmed5 ,for organising such a brilliant academic surgical event. The @SurgeonShow truly sets the tone for what lies ahead, showcasing the very best of global robotic surgical practice with a clear focus on improving patient outcomes. I am already looking forward to the Surgeon Show in 2027.

T minus 6 to the 10th Anniversary of @RoboUro NARUS 7 live surgeries Video shorts Focused tips Lively debates among experts But most important VEGAS Register Now: narus.us @drjkaouk @md_eun #alvingoh #isaackim @aghazimd @SimoneCrivella2 @RoboticsUrology @NNHarke @nikhilvasdevuro @ClaytonLauMD @jdhdavis @RoboDocX @RoboUroMD @Dr_TimWilson @drlesani @NYCRoboticTeam @JanetKukreja @DrRonneyAbaza @mdstifelman @JamesPorterMD @CraigRogersMD @DrJeanJoseph @davidleegumd @lee_c_zhao @UABUroOnc @ZLeeGU @TheMobotMD @benchallacombe @KGUROmd @RyanNelson762 @kdoersch689

The AI Impact Summit in Delhi has brought together the who’s who from the AI world. There is representation from over 100 countries. There are distinguished participants from every corner of the globe. Our aim is the same - leveraging the power of AI for the welfare of our planet.

📢 New publication in European Urology We are pleased to highlight a new study published in European Urology, titled "Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial". 👏 Congratulations to Hiroshi Kitamura et al. on this excellent contribution, together with all co-authors. 🔗 Read the full article here: 👉 lnkd.in/ePEvrQDY #EuropeanUrology #Urology #UroOncology #Research #MedicalResearch #AcademicUrology

Our study confirm Blue Light Cystoscopy significantly improves CIS detection and reveals MIBC and higher-risk disease missed on WLC , improving the managment of patients with suspected CIS and in the Re-Resection TURBT scenario. @enherts @UniofHerts @PhotocureASA mdpi.com/2673-4397/6/1/5

@tobiasmbuettner @brookmans76 @EUplatinum Completely agree. This is the future of Bladder cancer care.

@brookmans76 @EUplatinum THOR-2 is the proof that NMIBC is a molecularly heterogeneous disease that responds to precision oncology. The biology is solid; the hurdle is systemic toxicity. If TAR-210 can replicate this efficacy without the systemic burden, we are looking at a new standard of care.

🚨 Final THOR-2 results out in @EUplatinum - #Erdafitinib in FGFR-altered #NMIBC ✅ HR papillary NMIBC: • Median RFS not reached vs 11.6 mo with intravesical chemo • HR 0.25 (75% recurrence risk reduction) ✅ HR CIS ± papillary: • CR 94% at 8 wks | 81% at 32 wks • Median DoR 23.3 months ✅ Intermediate-risk NMIBC: • CR ~89% • Durable responses - median DoR not reached 👉Targeted systemic therapy showing real durability in IR and HR FGFR+ NMIBC #BladderCancer #TargetedTherapy @EUplatinum @oncodaily @urotoday @siadaneshmand @PignotG @nikhilvasdevuro @JimCatto @JNJInnovation